[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360538-105":59,"doc-detail-360538-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prediction-of-immune-related-adverse-events-in-urological-cancer-during-checkpoint-inhibitor-immunotherapy-original-research","Prediction of immune-related adverse events in urological cancer during checkpoint inhibitor immunotherapy - Original Research","","Immune checkpoint inhibitors (ICIs) have transformed the management of urological cancers, yet immune-related adverse events (irAEs)—particularly high-grade cases—pose a major threat to survival and prognosis. This retrospective study evaluated baseline blood tests, biochemical markers, and tumor expression of LCP1 and ADPGK in 112 patients treated with PD-1 or PD-L1 antibodies. LCP1 and ADPGK positivity, and especially the combined bivariate model, showed strong prediction of irAEs after ICI therapy (AUC 0.8415, 0.8759, and 0.9184). Performance remained robust across cancer types, with the bivariate model most accurate in bladder cancer (AUC 0.9856).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prediction-of-immune-related-adverse-events-in-urological-cancer-during-checkpoint-inhibitor-immunotherapy-original-research/360538/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prediction-of-immune-related-adverse-events-in-urological-cancer-during-checkpoint-inhibitor-immunotherapy-original-research/360538.png","ImageObject",300,407,{"name":92,"@type":93},"McGucket","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is predicting immune-related adverse events (irAEs) important in urological cancers treated with ICIs?","Question",{"text":112,"@type":113},"High-grade irAEs are a significant risk factor for survival and prognosis. Only a proportion of patients benefit from these drugs, so identifying those at higher risk is essential.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What patient data and biomarkers were analyzed in the study?",{"text":117,"@type":113},"The study assessed baseline blood tests, biochemical markers, and tumor expression of LCP1 and ADPGK in 112 patients receiving PD-1 or PD-L1 antibodies.",{"name":119,"@type":110,"acceptedAnswer":120},"How well did LCP1 and ADPGK predict irAEs after ICI treatment?",{"text":121,"@type":113},"LCP1 positivity, ADPGK positivity, and the combined bivariate model were highly predictive, with AUC values of 0.8415, 0.8759, and 0.9184 respectively. The bivariate model was especially accurate in bladder cancer (AUC 0.9856).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360538,1790230477,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1236954412713,"https://us-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Translational Oncology 70 (2026) 102836  \nContents lists available at ScienceDirect  \nTranslational Oncology  \njournal [homepage:](homepage: www.elsevier.com/locate/tranon)[ www.elsevier.com/locate/tranon](homepage: www.elsevier.com/locate/tranon)  \n| Original Research\u003Cbr>Prediction of immune-related adverse events in urological cancer during checkpoint inhibitor immunotherapy through immunohistochemical analysis of tumorous LCP1/ADPGK\u003Cbr>Liqing Xu a,1, Xi Zhang b,1, Zihao Tao a,1, Yiceng Yinga, Xueqin Zengc, Kaiwei Yanga, Yang Wang d, Ninghan Feng d,***, Xuesong Lia,*, Yaqian Lie,** , Qi Tang a,*\u003Cbr>a Department of Urology, Peking University First Hospital, Beijing, China\u003Cbr>b Comprehensive Internal Medicine, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China\u003Cbr>c Pathology Department, Renji Hospital of Shanghai Jiaotong University, Shanghai, China d Wuxi Second People's Hospital, No. 68 Zhongshan Road, Liangxi District, Wuxi, China\u003Cbr>e Beijing Liangjue Technology Co., LTD, Building 2, Zone 3, No. 186, South 4th Ring West Road, Fengtai District, Beijing, China |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords: Urological cancer PD-1\u003Cbr>PD-L1 irAE Biomarker LCP1\u003Cbr>ADPGK |  | Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of urological cancers. But immunerelated adverse events (irAEs), especially high-grade irAEs, are a significant risk factor for survival and prognosis in this group of patients. As such, the ability to predict irAEs is of great interest. We retrospectively examined baseline blood tests, biochemical markers, and tumor expression of LCP1 and ADPGK in 112 patients with urological cancers who received either PD-1 or PD-L1 antibodies. LCP1 positivity, ADPGK positivity, and more significantly, the bivariate model of LCP1 and ADPGK positivity were highly predictive of irAEs after ICI treatment, with area under the curve (AUC) of 0.8415, 0.8759, and 0.9184, respectively. These models performed well across various cancer types, and the bivariate model was particularly more accurate in predicting ICI-induced irAEs in bladder cancer (BC), with an AUC of 0.9856. Our retrospective study suggests that LCP1 positivity, ADPGK positivity, and the bivariate model of LCP1 and ADPGK positivity may be valuable predictive markers for ICI-induced irAEs. These results may help guide more targeted and personalized ICI treatment for patients with urological cancers. |\n\nIntroduction  \nIn the United States, it is estimated that 170,000 people are diagnosed with urological cancers and >32,000 die from urological cancers each year [1]. In China, a similar number of new cases is reported annually; however, over 65,000 deaths from urological cancers are reported each year [2]. Immunotherapy, especially immune checkpoint inhibitors (ICIs), has revolutionised the treatment of urological cancers [3]. ICIs are now available as first-line treatment for patients who are ineligible for platinum-based chemotherapy. For example, atezolizumaband pembrolizumab have shown objective response rates (ORRs) of  \n23.5% and 28.6%, respectively, in urothelial carcinoma [4–6]. Furthermore, first-line combination therapies of ICIs and chemotherapy, such as nivolumab plus cisplatin-based chemotherapy, have demonstrated improved overall survival (OS), progression-free survival (PFS), ORR, and complete response rates (CRR) compared to chemotherapy alone [7]. In addition, ICIs, such as nivolumab and avelumab, have also shown efficacy in the post-platinum and maintenance settings [8,9].  \nGiven the activation of the immune system by ICIs, there is a high risk of immune-related adverse events (irAEs) [3]. For instance, the incidence of grade ≥3 treatment-related adverse events (TRAEs) with pembrolizumab and atezolizumab monotherapy is 21.1% and 16%,  \n* Corresponding authors","cbCaimHlfYVzxKS9","https://ap.wps.com/l/cbCaimHlfYVzxKS9","pdf",8647520,"English","# Introduction\n## Immune checkpoint inhibitors and irAEs\n## Need for predictive biomarkers","[{\"question\":\"Why is predicting immune-related adverse events (irAEs) important in urological cancers treated with ICIs?\",\"answer\":\"High-grade irAEs are a significant risk factor for survival and prognosis. Only a proportion of patients benefit from these drugs, so identifying those at higher risk is essential.\"},{\"question\":\"What patient data and biomarkers were analyzed in the study?\",\"answer\":\"The study assessed baseline blood tests, biochemical markers, and tumor expression of LCP1 and ADPGK in 112 patients receiving PD-1 or PD-L1 antibodies.\"},{\"question\":\"How well did LCP1 and ADPGK predict irAEs after ICI treatment?\",\"answer\":\"LCP1 positivity, ADPGK positivity, and the combined bivariate model were highly predictive, with AUC values of 0.8415, 0.8759, and 0.9184 respectively. The bivariate model was especially accurate in bladder cancer (AUC 0.9856).\"}]","Prediction of immune-related adverse events in urological cancer during checkpoint inhibitor immunotherapy - Original Research | PDF",1790140461,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f2f9f22dd6a9b03ec653e6c816ab265.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a15339f7a3b66583c705b2b22ccf100.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aaa983ef84c488274d92d75eb18860d0.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93d1221799fb204782a2e2550414a7ee.webp",980,1306]